Purpose of this report

The purpose of this report is to provide feedback to the pediatric endocrinology community regarding content areas of strength and weakness, information which may be useful for identifying potential gaps in knowledge and guiding the development of educational materials. Using data from the American Board of Pediatrics' (ABP) Maintenance of Certification Assessment for Pediatrics (MOCA-Peds), this report summarizes diplomate performance on the questions within each of the 47 content areas assessed in 2022.

MOCA-Peds content areas

In 2022, MOCA-Peds—Pediatric Endocrinology consisted of questions from a total of 47 content areas, broken down as follows:

- 45 learning objectives¹ Each diplomate initially received one question from each of the 45 specific content areas drawn from the pediatric endocrinology content outline.
- Two featured readings¹ Each diplomate also received two questions per featured reading (eg, clinical guidelines, journal articles) for a total of four featured reading questions.

A pool of questions was developed for each learning objective and for each featured reading. Questions were then drawn from the pool and administered to diplomates throughout 2022 according to the specifications described in the bulleted list above.

Understanding this report

This report provides a graphical summary of diplomate performance on each of the 47 content areas assessed in 2022. Within the graphic and in the example below, the point (•) reflects the average percent correct for all questions within that learning objective or featured reading. The bar (—) reflects the range of percent correct values for the questions within that learning objective or featured reading. More specifically, the bar's lower endpoint indicates the most difficult question (ie, answered correctly by the lowest percentage of diplomates) and the bar's upper endpoint indicates the easiest question (ie, answered correctly by the highest percentage of diplomates).



¹Each diplomate also received 15 "repeat" questions selected from their original subset of learning objective and featured reading questions. Performance on the repeat administrations is not included in this report.

A note of caution

Many factors (eg, specific content of the question, wording of the question, plausibility of the incorrect answers) can impact diplomate performance on any question. It is thus difficult to determine if poor performance on a single question, or small set of questions, within a given content area reflects a true gap in diplomate knowledge or if the question(s) associated with that content area were difficult for other reasons (or some combination of both). Collectively, the entire set of MOCA-Peds questions (across all content areas) constitutes a psychometrically valid assessment of the diplomate's overall level of knowledge. Performance within a given content area is based on fewer questions, however, and is therefore less useful for making inferences about diplomate knowledge in that specific content area.

It is important to note again that for security reasons, a pool of questions was developed for each content area so that each diplomate received a unique set of questions. In addition, the number of questions can vary from one content area to the next. In cases where a content area had a relatively large pool of questions, the number of diplomates who answered each question was reduced, which diminished the statistical precision of each question's percent correct value. In cases where a content area had a relatively small number of questions, each question was answered by a larger number of diplomates, but the overall breadth of the content being assessed within that content area was constrained, which limits the generalizability of the results.

In other words, MOCA-Peds was designed to assess individual diplomates with respect to their overall level of knowledge in pediatric endocrinology. It was not designed to provide the pediatric community with diagnostic feedback pertaining to specific content areas within pediatric endocrinology. The results within this report may be informative and useful for that secondary purpose, but they should be interpreted with a degree of caution.

Additional notes

- To protect the security of the content of the assessment, the questions themselves, along
 with information about the number of questions in the pool for any particular learning
 objective or featured reading, are not provided in this report.
- This report contains data aggregated across many diplomates participating in the MOCA-Peds program and cannot be used to make inferences or draw conclusions regarding any particular diplomate.

2022 Content Area Feedback Report Pediatric Endocrinology

Learning Constitutional delay of publicity from hypogenactoripic hypogenadoripic hypogenadoripic Appropriation. 2. Appreciate the pattern of growth hormore (CRI) secretion in psychosocial deprivation. 3. Incorporate new advances in the management of adrenical-docystrophy. 4. Evaluate patients with DAX1 mutation. 5. Recognize the relative antidigenoity of different progestin preparations in rotal contraceptive pilis (CCPs). 6. ASMSS productire metabolic and brainfaire surgery guidelines, 2018 (Featured Reading) 7. The Clinical Spectrum of MCCiner-Abright Syndrome and its Management (Featured Reading) 8. Recognize the rote of adrenicocriticorophic hormone (ACTH) in addicatione secretion. 9. Defininguish revisious causes of nonemality hipperclaiment. 9. Defininguish revisious causes of nonemality hipperclaiment. 9. Defininguish revisious causes of nonemality hipperclaiment. 9. Defininguish revisious causes of nonemality hiperclaiment. 9. Recognize the endocrinor exposure to installing. 9. Recognize the endocrinor exposures to installing. 9. Recognize the endocrinor exposures to installing. 9. Recognize the endocrinor exposures to installing. 9. Product the most continuous opportunities of the production. 9. Product the most continuous opportunities device and continuous opportunities. 9. Product the most continuous opportunities opportunities opportunities. 9. Product the most continuous opportunities opportunities and continuous opportunities. 9. Describe the relation of the continuous opportunities and continuous opportunities. 9. Describe the relation of the continuous opportunities and continuous opportunities. 9. Des		Learning Objective	0	Perce	ent Co	rrect 75	100
2. Appreciate the pattern of grawth hormone (GH) secretion in psychococial deprivation. Positions patterns with DAX function.	_		<u> </u>				_
Evaluate patients with DAX1 mutation					- :	•	
Cocpus the relative androgenicity of different progestin preparations in oral contraceptive pills (OCPs).					_	•	_
S. Recognize the relative androgenicity of different progestin preparations in oral contraceptive pills (OCPs). 6. ASMSS pediatric metabolic and bariatric surgery guidelines, 2018 (Featured Reading) 7. The Clinical Specimum of McCune-Albright Syndrome and its Management (Featured Reading) 8. Recognize the role of adminisoritotrophic hormone (ACTH) in allosserines servertion. 9. Distinguish various causes of neonatal hypercalcentia. 10. Earlinguish mailed hyperthropic (ACTH) in allosserines servertion. 11. Identify risk factors for vitamin D deficiency: 12. Calculate and interpret sensitivity and specificity. 13. Recognize the endocrine response to fasting. 14. Interpret mean and standard deviation in normally distributed data sets. 15. Describe the endocrine response to fasting. 16. Recognize the risk factors for cerebral edema in diabetic ketoacidosis. 17. Differentiate clinical syndromes associated with serionin versus vasoacitive intestinal polypeptide (VIP) excess. 18. Differentiate clinical syndromes associated with serionin versus vasoacitive intestinal polypeptide (VIP) excess. 19. Predict the most common cognitive deficit in Klineliters syndrome. 10. Desgrabe the insk factors for drug treatment of elevated low-density lipoprotein (LDL) cholesterol in diabetics. 10. Diagnose a patient with insulin-like growth factor-1 (IGF-1) resistance. 10. Diagnose a patient with insulin-like growth factor-1 (IGF-1) resistance. 11. Diagnose a patient with insulin-like growth factor-1 (IGF-1) resistance. 12. Recommend the timing of thyroticectomy in a child with mutible endocrine neoplasia (MEN)2. 13. Manage a clinical with hypoprachiprodiem. 14. Diagnose a patient with insulin-like growth factor-1 (IGF-1) resistance. 15. Romo the medications that causes syndrome of inappropriate antiduretic hormone (ISIADH). 16. Diagnose in the indications of administration of administrat		• • • • • • • • • • • • • • • • • • • •				•	
COPPs) ASMBS pediatric metabolic and baristric surgery guidelines, 2018 (Featured Reading) The Clinical Spectrum of McCune-Albright Syndrome and its Management (Featured Reading) Recognize the trole of adrencoorticotrophic hormone (ACTH) in aldosterone secretion. Distinguish various causes of noronatal hypercaderia. Distinguish various causes of noronatal hypercaderia. Clinical Spectrum of McCune-Albright Syndrome and its Management (Featured Reading) Distinguish various causes of noronatal hypercaderia. Distinguish familial hyperthyroxinemic dysaburninemia from thyrotoxicosis. Calculate and interpret sensitivity and specificity. Calculate and interpret sensitivity and specificity. Recognize the endocrine response to Isaling. Interpret mean and standard deviation in normally distributed data sets. Distinguish the clinical phenotype of growth hormone (CH) resistance syndromes. Recognize the risk factors for cerebral edema in diabetic ketoacidosis. The Differentiate clinical syndromes associated with serotomin versus vaspactive intestinal polypeptide (VIP) excess. Differentiate between Cushing disease and ectopic adrencorritotrophic (ACTH) production. Prefetch the most common cognitive deficit in Klinefelter syndrome. Determine the indications for drug treatment of elevated low-density lipoprotein (LDL) cholesterol in diabetes. Disease and the string of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. Recomprete receive of each of allered by the direct feet thyroidectomy of the production of t						•	_
7. The Clinical Spectrum of McCune-Abright Syndrome and Its Management (Featured Reading) 8. Recognize the role of adenaconizonophic hormone (ACTH) in allosserone secretion. 9. Distinguish various causes of neonatal hypercalcemia. 10. Distinguish various causes of neonatal hypercalcemia. 11. Identity risk factors for visanio Deficiency. 12. Calculate and interpret sensitivity and specificity. 13. Recognize the endocroiner response to fissing. 14. Interpret mean and standard deviation in normally distributed data sets. 15. Describe the clinical phenotype of growth hormone (CH) resistance syndromes. 16. Recognize the inside phenotype of growth hormone (CH) resistance syndromes. 17. Differentiate clinical syndromes associated with serotonin versus vasociative intestinal polypopide (VIP) excess. 18. Differentiate between Cushing disease and ectopic adenocorticotrophic (ACTH) production. 19. Predict the most common cognitive deficit in Klinineliter syndrome. 19. Predict the most common cognitive deficit in Klinineliter syndrome. 20. Determine the indications for drug treatment of elevated low-density lipoprotein (LDL) cholesterol in diabetics. 21. Diagnose a patient with insulin-like growth factor-1 (IGF-1) resistance. 22. Recommend the timing of thyroidectomy in a child with multiple endocrine necplasia (MEN)2. 3. Manage a child with hypoparathyroidism. 4. Describe phenotypic consequences of translocation of SRY. 4. Describe phenotypic consequences of translocation of SRY. 5. Know the medications that cause syndrome of inappropriate antiduretic hormone (SADH). 4. Describe the effect of altered binding proteins on the direct free thyroine assay. 4. Evaluate disorders of testosterone biosynthesis. 4. Evaluate disorders of testosterone biosynthesis. 4. Evaluate disorders of testosterone biosynthesis. 5. Distributive the effect of various goald alteroid an explorational proteins on the direct free thyroine assay. 5. Distributive the effect of various goandal steroids on sex hormone-binding glo	5.					•	
Recognize the role of adrenocorticotrophic hormone (ACTH) in aldosterone secretion. Distinguish various causes of necessit hypercalcemia. —	6.	ASMBS pediatric metabolic and bariatric surgery guidelines, 2018 (Featured Reading)				•	-
Distinguish various causes of neonatal hypercalcemia.	7.	The Clinical Spectrum of McCune–Albright Syndrome and Its Management (Featured Reading)				─	_
10. Disinguish familial hyperthyroxinemic dysalbuminemia from thyrotoxicosis. 11. Identify risk factors for vitamin D deficiency. 2. Calculate and interpret sensitivity and specificity. 3. Recognize the endocrine response to fasting. 4. Interpret mean and standard deviation in normally distributed data sets. 5. Describs the clinical priently of growth hormone (GH) resistance syndromes. 6. Recognize the risk factors for cerebral edoma in diabetic ketoacidosis. 7. Differentiate clinical syndromes associated with serrotonin versus vasoacitive intestinal polypeptide (VIP) excess. 8. Differentiate between Cushing disease and ectopic adrenoconticotrophic (ACTH) production. 9. Predict the most common cognitive deficit in Kinefelter syndrome. 9. Determine the indications for drug treatment of elevated low-density lipoprotein (LDL) cholesterol in diabetes. 10. Diagnose a patient with insulin–like growth factor–1 (IGF-1) resistance. 11. Diagnose a patient with insulin–like growth factor–1 (IGF-1) resistance. 12. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasis (MEN)2. 13. Menage a child with hypoparatyropidism. 14. Describe phenotypic consequences of translocation of SRY. 15. Know the medications that cause syndrome of inappropriate anticularities hormone (SIADH). 16. Distinguish familial hypertohesterolemia from dyslipidemia associated with obesity. 17. Discribe the effect of altered binding proteins on the direct free thyroxine assay. 18. Evaluate discorders of trestociatore biosynthesis. 18. Evaluate direct in discordisor SPKOX gene testing. 18. Recognize the risk of associated autoimmune polyendocrinopathy syndrome type 1. 19. Recognize the risk of associated autoimmune polyendocrinopathy syndrome type 1. 19. Recognize the risk of associated autoimmune polyendocrinopathy syndrome type 1. 19. Recognize the risk of associated autoimmune polyendocrinopathy syndrome type 1. 20. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1.	8.	Recognize the role of adrenocorticotrophic hormone (ACTH) in aldosterone secretion.				•	
11. Identify risk factors for vitamin D deficiency. 12. Calculate and interpret sensitivity and specificity. 13. Recognize the endorrine response to fasting. 14. Interpret mean and standard deviation in normally distributed data sets. 15. Describe the clinical phenotype of growth hormone (GH) resistance syndromes. 16. Recognize the risk factors for cerebral edema in diabetic ketoacidosis. 17. Differentiate clinical syndromes associated with serotonin versus vasoactive intestinal polypeptide (VIP) occess. 18. Differentiate clinical syndromes associated with serotonin versus vasoactive intestinal polypeptide (VIP) occess. 18. Differentiate between Cushing disease and ectopic adrenocorticotrophic (ACTH) production. 19. Predict the most common cognitive deficit in Klinefelter syndrome. 10. Determine the indications for drug treatment of elevated low-density lipoprotein (LDL) cholesterol in diabetes. 21. Diagnose a patient with insulin-like growth factor—1 (IGF-1) resistance. 22. Recommend the timing of thyroridectomy in a child with multiple endocrine neoplasia (MEN)2. 23. Manage a child with hypoparathyroidism. 24. Describe the indications that cause syndrome of inappropriate antidiuretic hormone (SIADH). 25. Know the medications that cause syndrome of inappropriate antidiuretic hormone (SIADH). 26. Distinguish familial hypercholesterolemia from dyslipidemia associated with obesity. 27. Describe the effect of alterosterole biology proteins on the direct free thyroxine assay. 28. Evaluate disorders of testosterone biosynthesis. 29. Identify thow age and sex affect circulating insulin-like growth factor—1 (IGF-1) levels. 20. Identify the nodocrine presentations of autoimmune objevandorinopathy syndrome type 1. 30. Recognize the ink of associated autoimmune objevandorinopathy syndrome type 1. 31. Recognize the leftect of various gonadal steroids on sex hormone-binding globulin (SHBG). 32. Recognize the fetal complications in signaling defects in endocrine disorders. 33. Identify risk factors	9.	Distinguish various causes of neonatal hypercalcemia.				-	
12. Calculate and interpret sensitivity and specificity. 13. Recognize the endoorine response to fasting. 14. Interpret mean and standard deviation in normally distributed data sets. 15. Describe the clinical phenotype of growth hormone (GH) resistance syndromes. 16. Recognize the risk factors for cerebral edema in dabete ketoacdosis. 17. Differentiate clinical syndromes associated with serotonin versus vasoactive intestinal polypeptide (VIP) excess. 18. Differentiate clinical syndromes associated with serotonin versus vasoactive intestinal polypeptide (VIP) excess. 19. Predict the most common cognitive deficit in Klinefelter syndrome. 20. Determine the indications for drug treatment of elevated low-density lipoprotein (LDL) cholesterol in diabetes. 21. Diagnose a patient with insulin-like growth factor-1 (IGF-1) resistance. 22. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. 23. Manage a child with hypoparathyroidism. 24. Describe phenotypic consequences of translocation of SRY. 25. Know the medications that cause syndrome of inappropriate antidiuretic hormone (SIADH). 26. Distinguish familial hypercholesterolemia form dyslipidemia associated with obesity. 27. Describe the effect of altered binding proteins on the direct free thyroxine assay. 28. Evaluate disorders of testosterone biosynthesis. 29. Identify how age and sex affect circulating insulin-like growth factor-1 (IGF-1) levels. 20. Identify now age and sex affect circulating insulin-like growth factor-1 (IGF-1) levels. 20. Identify now age and sex affect circulating insulin-like growth factor-1 (IGF-1) levels. 20. Identify now age and sex affect circulating insulin-like growth factor-1 (IGF-1) levels. 21. Provide the indications for SHOX gene testing. 22. Recognize the incidence of complications of maternal type 1 diabetes. 23. Identify now age and sex affect insplantify defects in endocrine diseases in a child with type 1 diabetes. 24. Recognize the first of storder decembers in splan	10.	Distinguish familial hyperthyroxinemic dysalbuminemia from thyrotoxicosis.				-	—
13. Recognize the endocrine response to fasting. 14. Interpret mean and standard deviation in normally distributed data sets. 15. Describe the clinical phenotype of growth hormone (GH) resistance syndromes. 16. Recognize the risk factors for cerebral edema in dishelic ketoacidosis. 17. Differentiate clinical syndromes associated with serotorin versus vasoactive intestinal polypeptide (VIP) excess. 18. Differentiate between Cushing disease and ectopic adrenocorticotrophic (ACTH) production. 19. Predict the most common cognitive defict in Klinefelter syndrome. 20. Determine the indications for drug treatment of elevated low-density lipoprotein (LDL) cholesterol in disabotes. 21. Diagnose a patient with insulin-like growth factor-1 (IGF-1) resistance. 22. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. 23. Manage a child with hypoparathyroidism. 24. Describe phenotypic consequences of translocation of SRY. 25. Know the medications that cause syndrome of inappropriate antidiuretic hormone (SIADH). 26. Distinguish familial hypercholesterolemia from dyslipidemia associated with obesity. 27. Describe the effect of altered binding proteins on the direct free thyroxine assay. 28. Evaluate disorders of Isstosterone biosynthesis. 29. Identify how age and sex affect circulating insulin-like growth factor-1 (IGF-1) levels. 30. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. 31. Recognize the insid associated autoimmune diseases in a child with type 1 disbetes. 32. Recognize the first of associated autoimmune diseases in a child with type 1 disbetes. 33. Identify risk factors for iodine deficiency as an etiology of hypothyroidism. 34. Recognize the first of organize in spinaling defects in endocrine disorders. 35. Describe the role of G-protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone-insulin-like growth factor-1 (IGF-1) measurement in nutritional d	11.	Identify risk factors for vitamin D deficiency.			-	•	_
14. Interpret mean and standard deviation in normally distributed data sets. 15. Describe the clinical phenotype of growth hormone (GH) resistance syndromes. 17. Differentiate clinical syndromes associated with serotonin versus vasoactive intestinal polypeptide (VIP) excess. 17. Differentiate clinical syndromes associated with serotonin versus vasoactive intestinal polypeptide (VIP) excess. 18. Differentiate between Cushing disease and ectopic adrenocorticotrophic (ACTH) production. 19. Predict the most common cognitive deficit in Klinefelter syndrome. 20. Determine the indications for drug treatment of elievated low—density lipoprotein (LDL) cholesterol in diabetes. 21. Diagnose a patient with insulini–like growth factor-1 (IGF-1) resistance. 22. Recommend the timing of thyriodectomy in a child with multiple endocrine neoplasia (MEN)2. 24. Describe phenotypic consequences of translocation of SRY. 25. Know the medications that cause syndrome of inappropriate antidiuretic hormone (SIADH). 26. Distinguish familial hypercholesterolemia from dyslipidemia associated with obesity. 27. Describe the effect of altered binding proteins on the direct free thyroxine assay. 28. Evaluate disorders of testosterone biosynthesis. 29. Identify how age and sex affect circulating insulin–like growth factor-1 (IGF-1) levels. 20. Identify how age and sex affect circulating insulin–like growth factor-1 (IGF-1) levels. 21. Recognize the indications for SHOX gene testing. 22. Recognize the fetal complications of maternal type 1 diabetes. 23. Identify risk factors for iodine deficiency as an etiology of hypothyriodism. 24. Recognize the fetal complications in type 1 versus type 2 diabetes. 25. Discribe the fetal complications of maternal type 1 diabetes. 26. Distinguish various causes of hypophosphatemia. 27. Assess the incidence of complications in type 1 versus type 2 diabetes. 28. Describe the effect of various gonadal steroids on sex hormone–binding globulin (SHBG). 29. Apraise the use of glucagon for the di	12.	Calculate and interpret sensitivity and specificity.				•	
15. Describe the clinical phenotype of growth hormone (GH) resistance syndromes.	13.	Recognize the endocrine response to fasting.					_
16. Recognize the risk factors for cerebral edema in diabetic ketoscidosis. 17. Differentiate clinical syndromes associated with serotonin versus vasoactive intestinal polypeptide (VIP) excess. 18. Differentiate between Cushing disease and ectopic adrenocorticotrophic (ACTH) production. 19. Predict the most common cognitive deficit in Klinefelter syndrome. 20. Determine the indications for drug treatment of elevated low-density lipoprotein (LDL) cholesterol in diabetes. 21. Diagnose a patient with insulin-like growth factor-1 (IGF-T) resistance. 22. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. 23. Manage a child with hypoparathyroidism. 24. Describe phenotypic consequences of translocation of SRY. 25. Know the medications that cause syndrome of inappropriate antidiuretic hormone (SIADH). 26. Distinguish familial hypercholesterolemia from dyslipidemia associated with obesity. 27. Describe the effect of altered binding proteins on the direct free thyroxine assay. 28. Evaluate disorders of testosterone biosynthesis. 29. Identify how age and sex affect circulating insulin-like growth factor-1 (IGF-1) levels. 20. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. 21. Recognize the indications for SHOX gene testing. 22. Recognize the indications for SHOX gene testing. 23. Recognize the felot of priciations of material type 1 diabetes. 24. Recognize the felot of various gonadal steroids on sex hormone—binding globulin (SHBG). 25. Describe the tellor of complications in the pel 2 diabetes. 26. Differentiate the effect of various gonadal steroids on sex hormone—binding globulin (SHBG). 27. Assess the indicational complications of material type 1 diabetes. 28. Describe the effect of steroid excess on the growth hormone—insulin-like growth factor-1 (GH-IGF-1) axis. 38. Describe the effect of stress on the hypothalamic-pituitary-adrenal insufficiency. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinem	14.	Interpret mean and standard deviation in normally distributed data sets.				•	
17. Differentiate clinical syndromes associated with serotonin versus vasoactive intestinal polypeptide (VIP) excess. 18. Differentiate between Cushing disease and ectopic adrenocorticotrophic (ACTH) production. 19. Predict the most common cognitive deficit in Klinefelter syndrome. 20. Determine the indications for drug treatment of elevated low-density lipoprotein (LDL) cholesterol in diabetes. 21. Diagnose a patient with insulin-like growth factor-1 (IGF-1) resistance. 22. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. 23. Manage a child with hypoparathyroidism. 24. Describe phenotypic consequences of translocation of SRY. 25. Know the medications that cause syndrome of inappropriate antiduretic hormone (SIADH). 26. Distinguish familial hypercholesterolemia from dyslipidemia associated with obesity. 27. Describe the effect of altered binding proteins on the direct free thyroxine assay. 28. Evaluate disorders of testosterone biosynthesis. 29. Identify how age and sex affect circulating insulin-like growth factor-1 (IGF-1) levels. 20. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. 31. Recognize the indications for SHOX gene testing. 32. Recognize the indications for SHOX gene testing. 33. Identify inside active in deficiency as an etiology of hypothyroidism. 34. Recognize the fetal complications of maternal type 1 diabetes. 35. Describe the role of G-protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone-binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Osercibe the effects of steroid excess on the growth hormone-insulin-like growth factor-1 (IGF-1) measurement in nutritional deficiency. 38. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 49. Evaluate the pitfalls of insulin-like growth factor-1 (IGF-1) measurement in nutritional deficiency. 40. Distin	15.	Describe the clinical phenotype of growth hormone (GH) resistance syndromes.				-•	-
(VIP) excess. VIP) excess.	16.	Recognize the risk factors for cerebral edema in diabetic ketoacidosis.				-	_
18. Differentiate between Cushing disease and ectopic adrenocorticotrophic (ACTH) production.	17.	Differentiate clinical syndromes associated with serotonin versus vasoactive intestinal polypeptide			- :		
18. Differentiate between Cushing disease and ectopic adrenocorticotrophic (ACTH) production.		(VIP) excess.				•	1
19. Predict the most common cognitive deficit in Klinefelter syndrome. 20. Determine the indications for drug treatment of elevated low-density lipoprotein (LDL) cholesterol in diabetes. 21. Diagnose a patient with insulin-like growth factor-1 (IGF-1) resistance. 22. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. 23. Manage a child with hypoparathyroidism. 24. Describe phenotypic consequences of translocation of SRY. 25. Know the medications that cause syndrome of inappropriate antidiuretic hormone (SIADH). 26. Distinguish familial hypercholesterolemia from dyslipidemia associated with obesity. 27. Describe the effect of altered binding proteins on the direct free thyroxine assay. 28. Evaluate disorders of testosterone biosynthesis. 29. Identify how age and sex affect circulating insulin-like growth factor-1 (IGF-1) levels. 30. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. 31. Recognize the indications for SHOX gene testing. 32. Recognize the risk of associated autoimmune efiseases in a child with type 1 diabetes. 33. Identify risk factors for iodine deficiency as an etiology of hypothyroidism. 34. Recognize the feltal complications of maternal type 1 diabetes. 35. Describe the role of G-protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone-binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Oscribe the effect of steroid excess on the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 42. Evaluate the pitfalls of insulin-like growth factor-1 (IGF-1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the	18.			•			_
20. Determine the indications for drug treatment of elevated low-density lipoprotein (LDL) cholesterol in diabetes. 21. Diagnose a patient with insulin-like growth factor-1 (IGF-1) resistance. 22. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. 23. Manage a child with hypoparathyroidism. 24. Describe phenotypic consequences of translocation of SRY. 25. Know the medications that cause syndrome of inappropriate antidiuretic hormone (SIADH). 26. Distinguish familial hypercholesterolemia from dyslipidemia associated with obesity. 27. Describe the effect of altered binding proteins on the direct free thyroxine assay. 28. Evaluate disorders of testosterone biosynthesis. 29. Identify how age and sex affect circulating insulin-like growth factor-1 (IGF-1) levels. 30. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. 31. Recognize the insk of associated autoimmune polyendocrinopathy syndrome type 1. 32. Recognize the risk of associated autoimmune polyendocrinopathy syndrome type 1. 33. Identify risk factors for iodine deficiency as an etiology of hypothyroidism. 34. Recognize the fetal complications of maternal type 1 diabetes. 35. Describe the role of G-protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone-binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effect of steroid excess on the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 30. Distinguish various causes of acquired primary adrenal insulficiency. 40. Evaluate the pitfalls of insulin-like growth factor-1 (IGF-1) measurement in nutritional deficiency. 41. Recognize the action profile of insulin analogues. 42. Evaluate the pitfalls of insulin-like growth factor-1 (IGF-1) measurement in nutritional deficiency. 43. Recognize the act	19.				:	•	•
diabetes. Diagnose a patient with insulin–like growth factor–1 (IGF–1) resistance.		•					_
21. Diagnose a patient with insulin–like growth factor–1 (IGF–1) resistance. 22. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. 23. Manage a child with hypoparathyroidism. 24. Describe phenotypic consequences of translocation of SRY. 25. Know the medications that cause syndrome of inappropriate antidiuretic hormone (SIADH). 26. Distinguish familial hypercholesterolemia from dyslipidemia associated with obesity. 27. Describe the effect of altered binding proteins on the direct free thyroxine assay. 28. Evaluate disorders of testosterone biosynthesis. 29. Identify how age and sex affect circulating insulin–like growth factor–1 (IGF–1) levels. 30. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. 31. Recognize the indications for SHOX gene testing. 32. Recognize the fisk of associated autoimmune diseases in a child with type 1 diabetes. 33. Identify risk factors for lodine deficiency as an etiology of hypothyroidism. 34. Recognize the fetal complications of maternal type 1 diabetes. 35. Describe the role of G–protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone–binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the role of G–protein signaling defects in endocrine disorders. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter.						-) —
22. Recommend the timing of thyroidectomy in a child with multiple endocrine neoplasia (MEN)2. 23. Manage a child with hypoparathyroidism. 24. Describe phenotypic consequences of translocation of SRY. 25. Know the medications that cause syndrome of inappropriate antidiuretic hormone (SIADH). 26. Distinguish familial hypercholesterolemia from dyslipidemia associated with obesity. 27. Describe the effect of altered binding proteins on the direct free thyroxine assay. 28. Evaluate disorders of testosterone biosynthesis. 29. Identify how age and sex affect circulating insulin–like growth factor–1 (IGF–1) levels. 30. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. 31. Recognize the indications for SHOX gene testing. 32. Recognize the risk of associated autoimmune diseases in a child with type 1 diabetes. 33. Identify risk factors for iodine deficiency as an etiology of hypothyroidism. 34. Recognize the fetal complications of maternal type 1 diabetes. 35. Describe the role of G–protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone–binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. 38. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter.	21.	Diagnose a patient with insulin–like growth factor–1 (IGF–1) resistance.					_
Distinguish tamilial hypercholesterolemia from dysipidemia associated with obesity. Describe the effect of altered binding proteins on the direct free thyroxine assay. Evaluate disorders of testosterone biosynthesis. Didentify how age and sex affect circulating insulin—like growth factor—1 (IGF—1) levels. Didentify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. Recognize the indications for SHOX gene testing. Recognize the risk of associated autoimmune diseases in a child with type 1 diabetes. Didentify risk factors for iodine deficiency as an etiology of hypothyroidism. Recognize the fetal complications of maternal type 1 diabetes. Describe the role of G−protein signaling defects in endocrine disorders. Differentiate the effect of various gonadal steroids on sex hormone–binding globulin (SHBG). Assess the incidence of complications in type 1 versus type 2 diabetes. Describe the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. Possible the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. Possible the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. Distinguish various causes of hypophosphatemia. Possible the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. Recognize the action profile of insulin analogues. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis.				:	:	_	
Distinguish tamilial hypercholesterolemia from dysipidemia associated with obesity. Describe the effect of altered binding proteins on the direct free thyroxine assay. Evaluate disorders of testosterone biosynthesis. Didentify how age and sex affect circulating insulin—like growth factor—1 (IGF—1) levels. Didentify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. Recognize the indications for SHOX gene testing. Recognize the risk of associated autoimmune diseases in a child with type 1 diabetes. Didentify risk factors for iodine deficiency as an etiology of hypothyroidism. Recognize the fetal complications of maternal type 1 diabetes. Describe the role of G−protein signaling defects in endocrine disorders. Differentiate the effect of various gonadal steroids on sex hormone–binding globulin (SHBG). Assess the incidence of complications in type 1 versus type 2 diabetes. Describe the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. Possible the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. Possible the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. Distinguish various causes of hypophosphatemia. Possible the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. Recognize the action profile of insulin analogues. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis.				:	:		
Distinguish tamilial hypercholesterolemia from dysipidemia associated with obesity. Describe the effect of altered binding proteins on the direct free thyroxine assay. Evaluate disorders of testosterone biosynthesis. Didentify how age and sex affect circulating insulin—like growth factor—1 (IGF—1) levels. Didentify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. Recognize the indications for SHOX gene testing. Recognize the risk of associated autoimmune diseases in a child with type 1 diabetes. Didentify risk factors for iodine deficiency as an etiology of hypothyroidism. Recognize the fetal complications of maternal type 1 diabetes. Describe the role of G−protein signaling defects in endocrine disorders. Differentiate the effect of various gonadal steroids on sex hormone–binding globulin (SHBG). Assess the incidence of complications in type 1 versus type 2 diabetes. Describe the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. Possible the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. Possible the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. Distinguish various causes of hypophosphatemia. Possible the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. Recognize the action profile of insulin analogues. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis.				•	•	_	
Distinguish tamilial hypercholesterolemia from dysipidemia associated with obesity. Describe the effect of altered binding proteins on the direct free thyroxine assay. Evaluate disorders of testosterone biosynthesis. Didentify how age and sex affect circulating insulin—like growth factor—1 (IGF—1) levels. Didentify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. Recognize the indications for SHOX gene testing. Recognize the risk of associated autoimmune diseases in a child with type 1 diabetes. Didentify risk factors for iodine deficiency as an etiology of hypothyroidism. Recognize the fetal complications of maternal type 1 diabetes. Describe the role of G−protein signaling defects in endocrine disorders. Differentiate the effect of various gonadal steroids on sex hormone–binding globulin (SHBG). Assess the incidence of complications in type 1 versus type 2 diabetes. Describe the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. Possible the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. Possible the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. Distinguish various causes of hypophosphatemia. Possible the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. Recognize the action profile of insulin analogues. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis.				:	:	_	
27. Describe the effect of altered binding proteins on the direct free thyroxine assay. 28. Evaluate disorders of testosterone biosynthesis. 29. Identify how age and sex affect circulating insulin–like growth factor–1 (IGF–1) levels. 30. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. 31. Recognize the indications for SHOX gene testing. 32. Recognize the risk of associated autoimmune diseases in a child with type 1 diabetes. 33. Identify risk factors for iodine deficiency as an etiology of hypothyroidism. 34. Recognize the fetal complications of maternal type 1 diabetes. 35. Describe the role of G−protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone–binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.				:			•
28. Evaluate disorders of testosterone biosynthesis. 29. Identify how age and sex affect circulating insulin–like growth factor–1 (IGF–1) levels. 30. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. 31. Recognize the indications for SHOX gene testing. 32. Recognize the risk of associated autoimmune diseases in a child with type 1 diabetes. 33. Identify risk factors for iodine deficiency as an etiology of hypothyroidism. 44. Recognize the fetal complications of maternal type 1 diabetes. 55. Describe the role of G—protein signaling defects in endocrine disorders. 56. Differentiate the effect of various gonadal steroids on sex hormone–binding globulin (SHBG). 57. Assess the incidence of complications in type 1 versus type 2 diabetes. 58. Describe the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. 59. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter.		· · · · · · · · · · · · · · · · · · ·					•
29. Identify how age and sex affect circulating insulin–like growth factor–1 (IGF–1) levels. 30. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. 31. Recognize the indications for SHOX gene testing. 32. Recognize the risk of associated autoimmune diseases in a child with type 1 diabetes. 33. Identify risk factors for iodine deficiency as an etiology of hypothyroidism. 34. Recognize the fetal complications of maternal type 1 diabetes. 35. Describe the role of G-protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone–binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH-IGF–1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.		• • • • • • • • • • • • • • • • • • • •		•			•
30. Identify the endocrine presentations of autoimmune polyendocrinopathy syndrome type 1. 31. Recognize the indications for SHOX gene testing. 32. Recognize the risk of associated autoimmune diseases in a child with type 1 diabetes. 33. Identify risk factors for iodine deficiency as an etiology of hypothyroidism. 34. Recognize the fetal complications of maternal type 1 diabetes. 35. Describe the role of G−protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone−binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effects of steroid excess on the growth hormone−insulin−like growth factor−1 (GH−IGF−1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin−like growth factor−1 (IGF−1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic−pituitary−adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.		•		:	:	_	
31. Recognize the indications for SHOX gene testing. 32. Recognize the risk of associated autoimmune diseases in a child with type 1 diabetes. 33. Identify risk factors for iodine deficiency as an etiology of hypothyroidism. 34. Recognize the fetal complications of maternal type 1 diabetes. 35. Describe the role of G−protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone−binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effects of steroid excess on the growth hormone−insulin−like growth factor−1 (GH−IGF−1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin−like growth factor−1 (IGF−1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic−pituitary−adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.				:	:		•
32. Recognize the risk of associated autoimmune diseases in a child with type 1 diabetes. 33. Identify risk factors for iodine deficiency as an etiology of hypothyroidism. 34. Recognize the fetal complications of maternal type 1 diabetes. 35. Describe the role of G−protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone−binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effects of steroid excess on the growth hormone−insulin−like growth factor−1 (GH−IGF−1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin−like growth factor−1 (IGF−1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic−pituitary−adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.						_	
33. Identify risk factors for iodine deficiency as an etiology of hypothyroidism. 34. Recognize the fetal complications of maternal type 1 diabetes. 35. Describe the role of G−protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone–binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.				:	:	: <u> </u>	
34. Recognize the fetal complications of maternal type 1 diabetes. 35. Describe the role of G-protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone-binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effects of steroid excess on the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin-like growth factor-1 (IGF-1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic-pituitary-adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.		•		:	:		
35. Describe the role of G-protein signaling defects in endocrine disorders. 36. Differentiate the effect of various gonadal steroids on sex hormone-binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effects of steroid excess on the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin-like growth factor-1 (IGF-1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic-pituitary-adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.				:	:	_	
36. Differentiate the effect of various gonadal steroids on sex hormone-binding globulin (SHBG). 37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effects of steroid excess on the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin-like growth factor-1 (IGF-1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic-pituitary-adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.		· · · · · · · · · · · · · · · · · · ·		:		- : -	
37. Assess the incidence of complications in type 1 versus type 2 diabetes. 38. Describe the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.							
38. Describe the effects of steroid excess on the growth hormone–insulin–like growth factor–1 (GH–IGF–1) axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.						:	
axis. 39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.							
39. Appraise the use of glucagon for the diagnosis of hyperinsulinemic hypoglycemia. 40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin−like growth factor−1 (IGF−1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic−pituitary−adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.	30.						•
40. Distinguish various causes of hypophosphatemia. 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders. ■	20			:	:	:	
 41. Recognize different causes of acquired primary adrenal insufficiency. 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders. 				:	1	:	
 42. Evaluate the pitfalls of insulin–like growth factor–1 (IGF–1) measurement in nutritional deficiency. 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders. 							-
 43. Recognize the action profile of insulin analogues. 44. Assess the effect of stress on the hypothalamic-pituitary-adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders. 							
 44. Assess the effect of stress on the hypothalamic–pituitary–adrenal (HPA) axis. 45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders. 		· · · · · · · · · · · · · · · · · · ·					•
45. Manage a patient with euthyroid goiter. 46. Distinguish constitutional delay from growth disorders.							
46. Distinguish constitutional delay from growth disorders.		· · · · · · · · · · · · · · · · · · ·					•
47. Describe the potential adverse consequences of methimazole treatment.							•
	47.	Describe the potential adverse consequences of methimazole treatment.					